Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Uni-Bio Signs Up CR Zizhu to Market Recombinant Eye Treatment in China

publication date: Jul 13, 2016
Uni-Bio Science, a Hong Kong biopharma, signed an agreement that gives China Resources Zizhu Pharma China rights to market GeneSoft, an ophthalmic wound healing product. GeneSoft is a derivative of recombinant human epidermal growth factor (rhEGF), which improves healing of the cornea by regenerating the corneal epithelium. CR Zizhu, a wholly owned subsidiary of China Resource Pharma, focuses on the China hospital market for ophthalmology and reproductive health drugs. The initial term of the agreement is five years, with an option for an additional five years. More details....

Stock Symbol: (HK: 690)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital